Glycostem has developed a platform technology for the expansion and differentiation of allogeneic hematopoietic stem and progenitor cells derived from various sources like umbilical cord blood (UCB), bone marrow (BM) or mobilized peripheral blood (mPB).
Within the last years, Glycostem's platform technology enables a closed system cell culture process for the expansion of CD34+ hematopoietic stem and progenitor cells and further differentiation into fully functional immune cells, i.e. Natural Killer (NK) cells or antigen presenting cells such as dendritic cells.
The technology platform is based on the use of closed bioreactor systems in combination with a proprietary synthetic cell culture medium (GBGM - Glycostem Basal Growth Medium) and a patented combination of growth factors.
Glycostem has treated 10 elderly and fragile AML patients in a phase I setting with excellent safety profile and strong indication of clinical efficacy. Year 1 survival data showed 80% compared to population data showing 35%.
By late 2019 Glycostem expects to have GMP approved facilities utilising closed system technology resulting is the lowest possible production cost with off the shelf products for our pivotal clinical trial starting early 2020.
State of Ownership
Sales Account Executive, Springer Nature